secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001725160-26-000017
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Zentalis selects 400mg QD 5:2 azenosertib monotherapy as pivotal dose for Cyclin E1-positive ovarian cancer
--------------------------------------------------------------------------------

- Pre-specified interim analysis from DENALI Part 2a showed clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles.
- New DENALI Part 2c cohort to include ~40 patients previously treated with taxane-containing regimen for PROC, enrollment expected Q2 2026.
- Company expects to complete enrollment in all DENALI Part 2 cohorts and provide topline readout by year-end 2026.
- Azenosertib therapeutic profile supports advancement into confirmatory ASPENOVA Phase 3 trial and pre-commercial activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000017/0001725160-26-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000017/zntl-20260409.htm
  HTML page:      https://secwatch.observer/filing/0001725160-26-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer